Posted on February 26th, 2010 by Kelley Luckstein
Most pancreatic cancer patients die soon after diagnosis, but researchers have identified an oncogene that appears to be a promising new treatment target.
Even more hopeful is that drugs that target this oncogene are already approved to treat rheumatoid arthritis and are undergoing tests with colon and lung cancers, said lead researcher Nicole Murray, an assistant professor of pharmacology and senior associate consultant in the department of cancer basic science at the Mayo Clinic's Jacksonville, Fla., branch.
HealthDay, by Steven Reinerg, 2/26/2010
You must be logged-in to the site to post a comment.